Olsalazine

CHEMBL425 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

302.2 g/mol

LogP

3.1

Phase

4

An anti-inflammatory delivering mesalamine directly to the colon for ulcerative colitis maintenance.

Molekularmasse

302,2400 g/mol

LogP

3,10

TPSA

140,00 Å²

Lipinski-Regel der Fünf

Bestanden

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O

InChI

InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+

Molecular Formula

C14H10N2O6

HBD / HBA

4 / 8

Rotierbare Bindungen

4

Schwere Atome

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An anti-inflammatory delivering mesalamine directly to the colon for ulcerative colitis maintenance.

Yes, Olsalazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL425. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 22419. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Olsalazine auf PillFYI

Struktur

Schnelldaten

Formel: C14H10N2O6
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.